NASDAQ$IMNN
Celsion Corp · Q4 2019 earnings
Q4 2019 earnings · · Investor relations
Briefing
Celsion reported 2019 financial results and provided a business update.
Celsion reported a net loss of $16.9 million for the year ended December 31, 2019, with operating expenses at $21.1 million. The company highlighted progress with ThermoDox® and GEN-1 development programs and a strong balance sheet, anticipating key milestones in 2020.
- The pivotal 556-patient global Phase III OPTIMA Study in HCC was fully enrolled in August 2018.
- The second of two preplanned interim efficacy analyses is expected in June 2020.
- The OVATION 2 Study has completed enrollment of the first 15 patients in the Phase I portion of this 130-patient Phase I/II randomized study.
- Celsion received $1.9 Million Allocation Through the New Jersey Technology Business Tax Certificate Transfer (NOL) Program; with an Additional $2 Million More Expected in 2020.
Headline financials
Revenue & EPS history
Celsion · Revenue · Quarterly
$125K
Forward guidance
Celsion anticipates key milestones in 2020, including the interim efficacy analysis of the OPTIMA Study and continued progress in the OVATION 2 Study. They expect to receive net proceeds of $1.8 million from the sale of its 2017-2018 New Jersey state NOLs in the second quarter of 2020. An additional $2.0 million final allocation of NOL sales is fully expected in 2020.
Tailwinds
- The Company expects to receive net proceeds of $1.8 million from the sale of its 2017-2018 New Jersey state NOLs in the second quarter of 2020.
- An additional $2.0 million final allocation of NOL sales is fully expected in 2020.
- The OPTIMA Study is well positioned for success at the next preplanned interim efficacy analysis.
- GEN-1 Receives Orphan Drug Designation from the European Medicines Agency.
- Strengthened Balance Sheet Through a Timely $4.8 Million Registered Direct Offering.
Headwinds
- Unforeseen changes in the course of research and development activities and in clinical trials.
- The uncertainties of and difficulties in analyzing interim clinical data.
- The significant expense, time, and risk of failure of conducting clinical trials.
- The need for Celsion to evaluate its future development plans.
- Possible actions by customers, suppliers, competitors, regulatory authorities.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2019
+0.2%
Avg return
Earnings day
-2.1%
Avg return
5 days after
+3.5%
Avg return
30 days after
32%
12 / 38 earnings
Positive
+28.7%
Q3 2019
Best reaction
-12.8%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -1.1% | -8.8% | — | |
| Q2 2025 | -4.8% | -10.3% | -28.5% | |
| Q1 2025 | +2.5% | -40.0% | +107.5% | |
| Q4 2024 | +1.2% | +6.3% | +36.2% | |
| Q3 2024 | -12.8% | -17.0% | -10.6% | |
| Q2 2024 | -0.9% | +4.6% | +1.8% | |
| Q1 2024 | +7.2% | +1.4% | -11.6% | |
| Q4 2023 | +17.1% | +25.0% | +2.9% | |
| Q3 2023 | -4.0% | -3.0% | -9.1% | |
| Q2 2023 | -3.2% | -5.6% | -10.4% | |
| Q1 2023 | -5.2% | -6.7% | +3.7% | |
| Q4 2022 | -2.3% | -6.2% | +0.8% | |
| Q3 2022 | -3.9% | -4.6% | -11.1% | |
| Q2 2022 | -1.6% | -11.6% | -19.8% | |
| Q1 2022 | +0.4% | -7.5% | -23.5% | |
| Q4 2021 | -4.5% | +17.4% | -45.3% | |
| Q3 2021 | +1.2% | -10.7% | -22.6% | |
| Q2 2021 | -1.9% | -8.4% | +0.0% | |
| Q1 2021 | +4.0% | +12.1% | +54.5% | |
| Q4 2020 | -1.3% | -22.9% | -53.3% | |
| Q3 2020 | -1.9% | -3.7% | +24.1% | |
| Q2 2020 | +0.0% | -1.8% | -28.4% | |
| Q1 2020 | -1.5% | +26.5% | +125.0% | |
| Q4 2019 | +9.0% | -3.4% | +31.5% | |
| Q3 2019 | +28.7% | +34.3% | +50.0% | |
| Q2 2019 | +0.0% | +7.1% | +3.0% | |
| Q1 2019 | +6.1% | -4.2% | -15.4% | |
| Q4 2018 | -2.5% | +19.9% | +6.5% | |
| Q3 2018 | -4.2% | -12.6% | -8.8% | |
| Q2 2018 | -9.4% | -8.7% | +2.2% | |
| Q1 2018 | -1.6% | +1.2% | +0.0% | |
| Q4 2017 | -4.3% | -11.5% | -12.6% | |
| Q3 2017 | -5.2% | -5.7% | +32.1% | |
| Q2 2017 | -1.4% | -9.5% | -5.4% | |
| Q1 2017 | +0.0% | -8.3% | -14.0% | |
| Q4 2016 | +3.4% | -3.4% | +3.4% | |
| Q3 2016 | +0.0% | -10.9% | -27.2% | |
| Q2 2016 | +4.2% | +10.0% | +3.3% | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q2 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro